|Bid||35.58 x 4000|
|Ask||35.59 x 1400|
|Day's range||34.52 - 35.72|
|52-week range||27.88 - 43.23|
|Beta (5Y monthly)||0.68|
|PE ratio (TTM)||12.64|
|Forward dividend & yield||1.52 (4.49%)|
|Ex-dividend date||30 Jul 2020|
|1y target est||N/A|
PepsiCo CFO Hugh Johnston discusses the company's decision on spending on social media platforms.
New York hit another major milestone in recovering from the coronavirus outbreak, even as a majority of the U.S. continues to battle exponential case increases, with Florida setting a record in new diagnoses.
What happened Shares of BioNTech (NASDAQ: BNTX) were soaring 17.7% as of 10:57 a.m. EDT on Monday. The big gain came after BioNTech and its partner, Pfizer (NYSE: PFE), announced that two vaccine candidates being developed for SARS-CoV-2, the coronavirus that causes COVID-19, received Fast Track designation from the U.
The simplest way to benefit from a rising market is to buy an index fund. Active investors aim to buy stocks that...
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that two of the companies’ four investigational vaccine candidates from their BNT162 mRNA-based vaccine program (BNT162b1 and BNT162b2) being developed to help protect against SARS-CoV-2 (the virus that causes COVID-19), received Fast Track designation from the U.S. Food and Drug Administration (FDA). BNT162b1 and BNT162b2 are the two most advanced vaccine candidates in the BNT162 program currently being evaluated in ongoing Phase 1/2 clinical studies in the United States and Germany.
Investors often consider the healthcare sector a "defensive" one because people get sick in good economic times and bad. The healthcare sector has been thrown into turmoil with stay-at-home orders and clinic closures. BioNTech (NASDAQ: BNTX), NeoGenomics (NASDAQ: NEO), and Illumina (NASDAQ: ILMN) are three companies that should come through the pandemic era stronger than ever.
Pfizer and its German partner BioNTech on Monday announced two of their experimental coronavirus vaccines received 'fast track' designation from the U.S. Food and Drug Administration. ...meaning the FDA may decide on an approval within six months. If a vaccine candidate gets the green light, the companies said they expect to make up to 100 million doses by the end of this year. The companies said the recent testing of an experimental vaccine on 24 healthy volunteers showed that after 28 days they had developed higher levels of COVID-19 antibodies than typically seen in infected people. Upon regulatory approval, the companies expect to start a large trial with up to 30,000 participants… possibly later this month - paving the way toward a potential release of a vaccine. The U.S. and other countries have poured billions into developing a safe and effective vaccine for COVID-19. As of now - none are approved.
Moderna (NASDAQ: MRNA) has a date with Congress. Officials from those companies will field questions from the committee's oversight and investigations subcommittee on the current state of their vaccine development processes.
BioNTech (NASDAQ: BNTX) and Pfizer (NYSE: PFE) are right on the heels of Moderna (NASDAQ: MRNA) in the race to potentially develop a messenger RNA (mRNA) vaccine against SARS-CoV-2, the novel coronavirus that causes COVID-19. In an interview with The Wall Street Journal, BioNTech CEO Ugur Sahin predicted the companies will have enough data for a vaccine to be ready for approval by December. The companies are still trying to figure out which of multiple vaccine candidates should be taken into a 30,000-patient phase 2/3 clinical trial that is scheduled to start this month.
The U.S. saw yet another day of record coronavirus casualties on Thursday, led mostly by a relentless surge in the stricken Sun Belt region.
The pharma giant missed an opportunity for growth as breast cancer treatment Ibrance failed a key clinical trial.
The U.S. topped 3 million coronavirus cases Wednesday after setting a new record of 60,000 daily cases in the previous day.
Yahoo Finance speaks with NAACP CEO Derrick Johnson about Facebook's misinformation problems.
Shares of BioNTech (NASDAQ: BNTX) rose 34.8% last month, according to data provided by S&P Global Market Intelligence. The German biopharma announced progress in efforts to develop a safe and effective vaccine against SARS-CoV-2, the coronavirus that causes COVID-19, with partner Pfizer. In mid-June, BioNTech announced it had received access to roughly $112 million in debt financing from the European Investment Bank.
Pfizer (PFE) closed the most recent trading day at $34.03, moving -1.39% from the previous trading session.
Investors have reason to be excited after the update from Pfizer and BioNTech. Researchers evaluating the efficacy of COVID-19 vaccine candidates especially look for the production of antibodies that bind to the novel coronavirus and antibodies that neutralize the virus. Seven days after the second dosing of the vaccine, all participants who took the 10-microgram or 30-microgram dose had significantly elevated binding antibodies and neutralizing antibodies.
Here we discuss whether it will be wise to invest in momentum ETFs now as the U.S. manufacturing is showing signs of recovery along with improvements in the jobs market.
Facebook won't overcome the yawning advertiser revolt in response to hate content overnight, suggests a Goldman Sachs strategist that specializes in tech investing.
The encouraging progress with mRNA-based coronavirus vaccine drives meteoric rise in Moderna's (MRNA) shares. However, a rumored concern leads to correction.
As the coronavirus outbreak continues to aggravate, investors are eyeing developments in vaccine or treatments to combat the pandemic.
Pfizer (PFE) releases promising early results from its COVID-19 vaccine study. Several new drug/line extensions get approval in the United States, EU and Japan.
Pfizer (PFE) announces promising preliminary data on a vaccine candidate from its early-stage coronavirus program under which it is developing four mRNA-based vaccine candidates.
The Nasdaq and the S&P 500 closed higher on Wednesday as investors focused on signs of economic recovery and better than expected economic data.